Efficacy of Surufatinib in Western Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNETs)
Introduction: Surufatinib is a targeted inhibitor of tyrosine kinases VEGFR1, 2, & 3, FGFR1, and CSF-1R. The safety profile was favorable in 2 completed studies (NCT02133157, NCT02267967) conducted in China. A recent phase 3 placebo controlled study (NCT02588170) confirmed safety, and demonstrated superior efficacy (PFS: 9.2 v 3.8 months) of Surufatinib in Chinese pts with advanced extra-pancreatic NETs (epNET).
Aim(s): The primary objective of dose EXP is to evaluate the anticancer activity in pts with select solid tumors including PanNETs or epNETs at recommended dose of 300mg QD.
Materials and methods: A dose escalation (ESC)/expansion (EXP) study is being conducted in the United States (US) to establish safety and efficacy in Western pts. The ESC phase enrolled 35 pts of any solid tumor and is complete.
Conference: 17th Annual ENETSConcerence (2020)
To read the full abstract, please log into your ENETS Member account.